Chung Hyung-min

Last updated
Chung Hyung-min
jeonghyeongmingyosunim Hyung Min Chung.jpg
Chung Hyung-min
Born1964 (age 60–61)
South Korea
Nationality South Korean
Alma mater Konkuk University
Known forAnimal Biotechnology & Stem cell research
Awards2004: Society for Assisted Reproductive Technology (SART) Prize Paper
2009: "CEO of Next generation" (for Bio Technology), Ministry of Knowledge Economy
Scientific career
Fields Stem cell research
InstitutionsCHA Stem Cell Institute, CHA University
Doctoral advisor Chung Kil-saeng

Chung Hyung-min (born 1964) is a South Korean biotechnology professor. [1] [2] [3] He was appointed professor at CHA University in 1997 after obtaining his BA, MA and Ph.D degree at Konkuk University.

Contents

Currently, he is a professor of biomedical science at CHA University, Director of CHA Stemcell Institute, President of CHA Bio & Diostech Inc., Member of LMO Assessment Advisory Committee for Ministry of Health and Welfare, and Advisor for the Ministry of Knowledge Economy under the National Technical Advisory Committee. Dr Chung is a prominent leader in the field of stem cell research with over 20 years of experience.

His research aims at the development of stem cell therapies using human adult and embryonic stem cells. Primarily, his study focusses on the clinical applications of human embryonic stem cell-derived retinal cells, artificial blood and cardiovascular cells.

His research group became only the second in the world to be approved[ citation needed ] to conduct clinical application of human embryonic stem cells for the treatment of an orphan disease named Stargardt's macular dystrophy.[ citation needed ]

Education

Awards

Publications

  1. Lee, MJ; Kim, J; Lee, KI; Shin, JM; Chae, JI; Chung, HM (2011). "Enhancement of wound healing by secretory factors of endothelial precursor cells derived from human embryonic stem cells". Cytotherapy. 13 (2): 165–78. doi:10.3109/14653249.2010.512632. PMID   21235296.
  2. Kim, MJ; Park, JS; Kim, S; Moon, SH; Yang, HN; Park, KH; Chung, HM (2011). "Encapsulation of bone morphogenic protein-2 with Cbfa1-overexpressing osteogenic cells derived from human embryonic stem cells in hydrogel accelerates bone tissue regeneration". Stem Cells and Development. 20 (8): 1349–58. doi:10.1089/scd.2010.0311. PMID   21126165.
  3. Kim, EY; Jeon, K; Park, HY; Han, YJ; Yang, BC; Park, SB; Chung, HM; Park, SP (2010). "Differences between cellular and molecular profiles of induced pluripotent stem cells generated from mouse embryonic fibroblasts". Cellular Reprogramming. 12 (6): 627–39. doi:10.1089/cell.2010.0013. PMC   2998986 . PMID   20958217.
  4. Moon, SH; Kim, JS; Park, SJ; Lim, JJ; Lee, HJ; Lee, SM; Chung, HM (2011). "Effect of chromosome instability on the maintenance and differentiation of human embryonic stem cells in vitro and in vivo". Stem Cell Research. 6 (1): 50–9. doi:10.1016/j.scr.2010.08.006. PMID   20920899.
  5. Park, SW; Jun Koh, Y; Jeon, J; Cho, YH; Jang, MJ; Kang, Y; Kim, MJ; Choi, C; et al. (2010). "Efficient differentiation of human pluripotent stem cells into functional CD34+ progenitor cells by combined modulation of the MEK/ERK and BMP4 signaling pathways". Blood. 116 (25): 5762–72. doi: 10.1182/blood-2010-04-280719 . PMID   20884805.

References

  1. ↑ "Stem cells bring life to biotech industry". JoongAng Ilbo . 2012-01-25. Retrieved 2014-07-12.
  2. ↑ "Bioethics body approves first embryonic stem cell test". The Korea Herald . 2011-04-27. Retrieved 2014-07-12.
  3. ↑ "South Korea to Lift Ban On Human Stem Cell Research". U.S. News & World Report. 2009-04-29. Retrieved 2014-07-12.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.